Treatment
48Cardiac amyloidosis therapy reference (2026)
Reference snapshot of cardiac amyloidosis therapy across AL and ATTR types.
Achondroplasia therapy reference (2026)
Reference snapshot of achondroplasia care across supportive, surgical, and disease-modifying tiers.
Treatment-resistant schizophrenia therapy reference (2026)
Reference snapshot of TRS therapy across clozapine, augmentation, and emerging mechanism tiers.
Retinal vein occlusion therapy reference (2026)
Reference snapshot of RVO therapy across acute and ongoing macular edema management plus systemic care integration.
Thyroid cancer therapy reference (2026)
Reference snapshot of thyroid cancer therapy across differentiated, medullary, and anaplastic subtypes.
Allergic bronchopulmonary aspergillosis therapy reference (2026)
Reference snapshot of ABPA therapy across acute, recurrent, and emerging biologic-integrated tiers.
Systemic sclerosis therapy reference (2026)
Reference snapshot of systemic sclerosis therapy across organ-domain-specific and emerging disease-modifying tiers.
Nausea and vomiting in pregnancy therapy reference (2026)
Reference snapshot of nausea and vomiting in pregnancy therapy from mild morning sickness through hyperemesis gravidarum.
Cholangiocarcinoma therapy reference (2026)
Reference snapshot of cholangiocarcinoma therapy across resectable and advanced disease and biomarker-defined targeted tiers.
ANCA-associated vasculitis therapy reference (2026)
Reference snapshot of ANCA-associated vasculitis therapy across induction, maintenance, and refractory disease.
Chronic inflammatory demyelinating polyneuropathy therapy reference (2026)
Reference snapshot of CIDP therapy across induction, maintenance, and emerging biologic tiers.
Lipid management therapy reference (2026)
Reference snapshot of lipid management therapy across foundational, add-on, and emerging tiers.
Overactive bladder therapy reference (2026)
Reference snapshot of overactive bladder therapy across behavioural, pharmacological, and procedural tiers.
Allergic conjunctivitis therapy reference (2026)
Reference snapshot of allergic conjunctivitis therapy across mild seasonal, persistent, severe, and emerging tiers.
Phenylketonuria therapy reference (2026)
Reference snapshot of PKU therapy across newborn-screened, paediatric, and adult populations.
Autism spectrum disorder care reference (2026)
Reference snapshot of ASD care across behavioural therapy, educational support, pharmacotherapy for associated symptoms, and emerging core-symptom programs.
Severe COPD therapy reference (2026)
Reference snapshot of severe COPD therapy across foundational inhaler, biologic, and emerging mechanism tiers.
Spasticity therapy reference (2026)
Reference snapshot of spasticity therapy across post-stroke, multiple sclerosis, cerebral palsy, and spinal cord injury populations.
Tobacco use disorder therapy reference (2026)
Reference snapshot of tobacco use disorder therapy across pharmacotherapy, behavioural support, and integrated care models.
Spinal muscular atrophy therapy reference (2026)
Reference snapshot of SMA therapy options across newborn-screened, symptomatic infant, child, and adult populations.
Lupus nephritis therapy reference (2026)
Reference snapshot of lupus nephritis therapy across induction and maintenance phases.
Presbyopia therapy reference (2026)
Reference snapshot of presbyopia management across optical, surgical, and pharmacological approaches.
Obstructive sleep apnea therapy reference (2026)
Reference snapshot of OSA therapy across positive airway pressure, oral appliances, surgery, neurostimulation, and emerging pharmacotherapy.
HFrEF therapy reference (2026)
Reference snapshot of HFrEF therapy across the four-pillar standard, additional approved options, and emerging mechanism classes.
Adult diffuse glioma therapy reference (2026)
Reference snapshot of adult diffuse glioma therapy across IDH-mutant grade 2/3 disease, glioblastoma first-line, and recurrent disease.
Vasomotor symptom therapy reference (2026)
Reference snapshot of vasomotor symptom therapy across hormone, non-hormonal pharmacotherapy, and emerging mechanism-targeted tiers.
Sjogren disease therapy reference (2026)
Reference snapshot of Sjogren disease therapy across symptomatic, off-label, and emerging mechanism-targeted tiers.
Hereditary angioedema therapy reference (2026)
Reference snapshot of HAE prophylaxis and on-demand therapy options.
Refractory chronic cough therapy reference (2026)
Reference snapshot of refractory chronic cough therapy across symptomatic, off-label, and emerging targeted tiers.
Thyroid eye disease therapy reference (2026)
Reference snapshot of thyroid eye disease therapy across active and stable phases.
OCD therapy reference (2026)
Reference snapshot of OCD therapy across pharmacotherapy, psychotherapy, and procedural-and-emerging tiers.
Hepatocellular carcinoma therapy reference (2026)
Reference snapshot of HCC therapy across early, intermediate, and advanced disease.
Acute ischemic stroke therapy reference (2026)
Reference snapshot of acute ischemic stroke therapy across thrombolysis and mechanical thrombectomy.
Type 1 diabetes therapy reference (2026)
Reference snapshot of T1D therapy across insulin delivery, disease modification, and beta-cell replacement.
Postmenopausal osteoporosis therapy reference (2026)
Reference snapshot of postmenopausal osteoporosis therapy across anti-resorptive and anabolic tiers.
Migraine prevention therapy class reference (2026)
Reference snapshot of approved migraine prevention options including CGRP class, traditional preventives, and emerging mechanisms.
Antisense oligonucleotide platform landscape (2026 reference)
Reference snapshot of approved ASO therapies, late-stage programs, and the delivery and chemistry platforms behind them.
Anti-amyloid antibody landscape, 2026 mid-year reference
A dated reference snapshot of the anti-amyloid antibody class for Alzheimer's disease as of mid-2026: approved products, withdrawn products, late-stage pipeline, label-defining clinical evidence, and the operational pattern that defines the class.
Bipolar disorder treatment landscape, 2026 mid-year reference
Reference layout of the bipolar disorder treatment landscape as of mid-2026: mood stabilisers, atypical antipsychotics, antidepressant adjuncts, the depression-versus-mania-versus-maintenance prescribing logic, and the live commercial questions across the pipeline.
COPD pipeline expansion, 2026 mid-year reference
Reference layout of the COPD therapeutic pipeline as of mid-2026: established inhaled bronchodilator and inhaled corticosteroid combinations, the emerging biologic class (anti-IL-5, anti-IL-33, anti-TSLP), novel small-molecule mechanisms, and the live commercial questions across the pipeline.
Rare disease enzyme replacement therapy landscape, 2026 mid-year reference
Reference layout of the enzyme replacement therapy class in rare disease as of mid-2026: approved assets across lysosomal storage disease, the next-generation engineered-enzyme programs, the gene therapy alternatives, and the live commercial questions including chronic-infusion burden and CNS access.
IBD biologic and small-molecule landscape, 2026 mid-year reference
Reference layout of the IBD therapeutic class as of mid-2026: approved biologics (anti-TNF, anti-integrin, IL-12/23, IL-23), oral small molecules (JAK, S1P modulators, TYK2 in pipeline), and the live commercial questions including line-of-therapy positioning and combination strategy.
Glaucoma treatment landscape, 2026 mid-year reference
Reference layout of the glaucoma treatment landscape as of mid-2026: pressure-lowering eye drop classes, sustained-release drug-delivery implants, microinvasive glaucoma surgery, and the live commercial questions including adherence, procedure-room capacity, and the next-generation pipeline.
ATTR cardiomyopathy treatment landscape, 2026 mid-year reference
Reference layout of the ATTR cardiomyopathy treatment landscape as of mid-2026: TTR stabilisers, TTR silencers, the diagnostic-pathway infrastructure, and the live commercial questions including diagnostic-pathway expansion and combination therapy.
Psoriasis biologics landscape, 2026 mid-year reference
Reference layout of the psoriasis biologic class as of mid-2026: approved mechanisms, first-line versus later-line positioning, the IL-23 dominance picture, and the live commercial questions for the class.
DMD treatment landscape, 2026 mid-year reference
Reference layout of the Duchenne muscular dystrophy treatment landscape as of mid-2026: approved mechanisms across exon-skipping, gene therapy, and corticosteroid-class agents, late-stage pipeline, and the live commercial questions across patient populations.
Approved gene therapies by indication, 2026 mid-year reference
Reference layout of approved in vivo and ex vivo gene therapies as of mid-2026: indications, mechanism, delivery vector or platform, regulatory pathway, and the live commercial questions for each.
Disease-modifying therapies in Alzheimer's, as of Q2 2026
Two anti-amyloid antibodies have traditional FDA approval; subcutaneous formulations are advancing; the post-amyloid pipeline is portfolio-shaped.
Diagnosis
2Dementia subtype therapy reference (2026)
Reference snapshot of dementia therapy across Alzheimer's, dementia with Lewy bodies, vascular, and frontotemporal subtypes.
Alzheimer's diagnostic pathways, as of Q2 2026
Plasma biomarkers are entering routine workflows alongside established CSF and PET options, with confirmatory imaging still standard before disease-modifying therapy.
Regulatory
1Access
2Caregiver support landscape for Alzheimer's disease, as of Q2 2026
A reference view of the federal, state, employer, and direct-support programs that currently exist for unpaid family caregivers of people with Alzheimer's disease in the US, with notes on the UK and EU.
Payer coverage for anti-amyloid therapy, as of Q2 2026
A reference view of how anti-amyloid therapy is currently covered across US Medicare, Medicare Advantage, US commercial payers, and select international markets.
Pipeline
8Bispecific antibody class landscape in oncology, 2026 mid-year reference
Reference layout of the bispecific antibody class in oncology as of mid-2026: approved assets across haematology and solid tumours, the T-cell engager subclass, the dual-checkpoint subclass, and the live commercial questions including site-of-care infrastructure and combination strategy.
Maternal mental health pipeline, 2026 mid-year reference
Reference layout of the maternal mental health pipeline as of mid-2026: approved mechanisms for postpartum depression, late-stage assets for perinatal mood disorders and adjacent indications, and the live commercial questions including screening pathway and access frame.
Retinal therapy pipeline, 2026 mid-year reference
Reference layout of the retinal therapy pipeline as of mid-2026: approved mechanisms across wet AMD, DME, GA, and inherited retinal dystrophy, late-stage pipeline by mechanism, and the live commercial questions including delivery innovation, biosimilar dynamics, and gene-therapy progress.
Treatment-resistant depression pipeline, 2026 mid-year reference
Reference layout of the treatment-resistant depression pipeline as of mid-2026: approved mechanisms, late-stage assets, the psychedelic and ketamine-class programs, novel non-monoamine mechanisms, and the live commercial questions across the pipeline.
Obesity drug pipeline, 2026 mid-year reference
Reference layout of the obesity drug pipeline as of mid-2026: approved mechanisms, late-stage assets, the dual and triple agonist class, and the live commercial questions including manufacturing capacity, cardiovascular outcomes, and the indication-by-indication coverage frame.
Endometriosis pipeline, 2026 mid-year reference
Reference layout of the endometriosis pipeline as of mid-2026: approved mechanisms, late-stage assets, the GnRH antagonist class, the non-hormonal pipeline, and the live commercial questions including diagnosis-pathway access and the surgical-medical interplay.
ADC class landscape, 2026 mid-year reference
Reference layout of the antibody-drug conjugate class in oncology as of mid-2026: approved assets by target and indication, late-stage pipeline by mechanism, and the live differentiation axes the field is settling on.
Alzheimer's drug development pipeline, as of Q2 2026
A reference view of the late-stage Alzheimer's pipeline as of Q2 2026 - tau-directed programs, GLP-1 receptor agonists, neuroinflammation, synaptic and neuronal resilience, and genetic/protein-clearance approaches.
Drug development
2What we are watching in Alzheimer's, as of Q2 2026
A reference list of the threads PatientSpotlight is actively tracking - clinical readouts, regulatory and reimbursement decisions, real-world evidence accumulation, and operational rollout. Each thread names what to watch and why it matters, without predicting when it will resolve.
Clinical trial endpoints in Alzheimer's disease, as of Q2 2026
A reference view of the cognitive, functional, and biomarker endpoints used in late-stage Alzheimer's trials - what each measures and how to read a readout that uses it.